FDA approves first disease-modifying therapy for type 1 diabetes
Drug Discovery World
NOVEMBER 21, 2022
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for anti-CD3-directed antibody TZIELD (teplizumab-mzwv), the first immunomodulatory treatment for type 1 diabetes (T1D). . The company also offers financial assistance options to eligible patients for out-of-pocket costs. . .
Let's personalize your content